Deva, a local and rooted pharmaceutical company, has been operating in Turkey since 1958. With 3 production plants and approximately 1800 employees, Deva produces and markets drugs for human use, as well as APIs, veterinary drugs, colognes, and medical vials. It offers products in 13 diversified therapeutic areas ranging from oncology to cardiology, from respiratory system to nervous system. In addition, the company provides syrups, drops, sprays, creams, gels, suppositories, aerosol inhalers, tablets, film tablets, capsules, powder suspensions, and medical ampoules. Focusing on R&D, Deva develops innovative new forms and products of high added value at its R&D centre with a competent team of approximately 170 scientists.
With its growing international operations, Deva has around 300 licenses in many countries including EU countries such as Germany, the Netherlands, Switzerland and UK through agreements with pharmaceutical firms and distributors under the Deva brand name, as well as through license agreements; and provides contract manufacturing services. Deva Holding A.S is a subsidiary of EastPharma S.a.r.l.
Contact Details
Deva Holding AS
Halkali Merkez Mah. Press Express Avenue KÜÇÜKÇEKMECE / ISTANBUL
Tel:0 (212) 692 92 92 (PBX)
Fax:0 (212) 697 00 24
Email:The info@deva.com.tr
Website: www.deva.com.tr/
Murat Barlas, the longest serving board member for the Turkish Pharmaceutical Manufacturers Association, discusses the need for a new perspective in government-industry relations in the Turkish pharmaceutical industry, and the…
The Turkish minister of labour and social security comments on the country’s deep commitment to providing for the health of citizens while maintaining sustainability and continuous improvement of services. How…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Turkey is a key market in the region for Servier, says general manager Philippe Méa, largely due to the country’s relatively strong and stable vision for the healthcare industry. The…
Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness…
Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently…
Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years. How did Medipol come into existence,…
Professor Burak Erman, the leader of the Drug Research Center at Koç University, and his colleague Hakan Orer, discuss the early activities of the center as a catalyst for collaboration…
Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement.…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim…
Turkey’s Minister of Health discusses the major achievements of his party in the area of healthcare since 2003, and the key priorities for the country’s healthcare system moving forward. During…
See our Cookie Privacy Policy Here
